Propanc Biopharma (NASDAQ:PPCB), a biopharmaceutical company focused on novel cancer treatments, has announced its uplisting to the Nasdaq Capital Market and pricing of a $4 million public offering. The company is offering 1,000,000 shares at $4.00 per share, with an additional 45-day option for underwriters to purchase up to 150,000 shares.
Trading on Nasdaq is set to begin on August 15, 2025, transitioning from the OTC Markets Pink Tier. The offering, expected to close on August 18, 2025, will be managed by D. Boral Capital LLC and Craft Capital Management LLC. Proceeds will be used for working capital and general business purposes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.